

Press Release
30 August 2004

**Hua Han to sign MOU with Rocheby biomed
for the launch of the world's first rapid diagnostic test kit
CanDia5® in China
to reach over 600 million female market**

【 Hong Kong - 30 August 2004 】 Hua Han Bio-Pharmaceutical Holdings Limited ("Hua Han," stock code 0587) today announced that it has signed a Memorandum of Understanding with Rocheby biomed Limited ("Rocheby biomed," ASX:RBY) for the rollout of its lead product, CanDia5®, throughout mainland China.

CanDia5®, the world's first rapid diagnostic test for vaginal thrush is a non-invasive, simple to use, point-of-care test kit developed in Australia. Under the terms of the deal Rocheby biomed will appoint Hua Han Bio-Pharmaceutical as its exclusive sales, marketing and distribution partner in China for CanDia5®.

The China deal extends Rocheby's marketing and distribution network for CanDia5® to eight countries including Australia, New Zealand, Malaysia, Vietnam, Singapore, India and Hong Kong.

Hua Han Bio-Pharmaceutical has a strong distribution network and resources to enable CanDia5® to gain significant traction in the Chinese market.

Thrush is a common medical problem among women in the 20 to 45 year age group, and it is estimated that the condition will affect 75% of sexually active women in China at least once during their lifetime and a high proportion of those will experience multiple bouts. CanDia5® remains the only product of its type in the world.

The Rocheby CanDia5® test kits will be marketed to pathology and medical laboratories, medical practitioners and allied health practitioners across China.

About Rocheby

Rocheby biomed is an ASX-listed biotechnology company engaged in the research, development and marketing of products for the diagnosis and treatment of fungal infections in humans. The company's main market is that of in-vitro diagnostic testing which covers serology tests in

hospitals as well as point-of-care products for use by consumers or health professionals operating outside hospitals.

CanDia5® can accurately detect Candida (thrush) antibodies using a drop of patient's blood. The kit is positioned as a point-of-care test kit for use by general practitioners and specialists in obstetrics and gynaecology for diagnosis of women presenting with suspected vaginal thrush.

About Hua Han Bio-Pharmaceutical Holdings Ltd

Hua Han Bio-Pharmaceutical Holdings Ltd is engaged in the research and development, manufacture and sales of gynecological medicine and medicinal healthcare products for women. Hua Han Bio-Pharmaceutical produces approximately 30 types of products from over 40 medicine licences. The company has 8 production lines that are GMP accredited in China and 3 professional pharmaceutical sales and marketing companies under the group are GSP accredited. Hua Han Bio-Pharmaceutical employs over 1,000 professional sales representatives, covering more than 3,000 hospitals, about 20,000 retailing drug stores and 5,000 supermarkets. In 1st half FY04, Hua Han's sales grew over 130% to HK\$237 million compared to the previous corresponding period.

For more than a decade through its R&D, production and sales activities the company has built an exceptional understanding of the gynaecology and women's health market in China and is highly experienced in the operations of these markets. Hua Han Bio-Pharmaceutical is one of the most prestigious pharmaceutical enterprises in China specializing in the manufacture and sales of gynaecological pharmaceutical and healthcare products and has sales offices in 29 major provinces and municipalities in China.